Investor Relations

Overview

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

Upcoming

September 18, 2019 12:10 PM BST
Bank of America Merrill Lynch Global Healthcare Conference

September 10, 2019 12:55 PM EDT
Morgan Stanley 17th Annual Global Healthcare Conference

Prior

July 30, 2019 8:00 AM EDT
Q2 2019 Incyte Corporation Earnings Conference Call

June 17, 2019 8:00 AM EDT
Ruxolitinib Cream: Phase 2 Data in Vitiligo Webcast

June 11, 2019 2:00 PM PDT
Goldman Sachs 40th Annual Global Healthcare Conference

SEC Filings

Filing date Description Filing Group View

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Statement of changes in beneficial ownership of securities

3,4,5

Investor Contacts

Michael Booth D.Phil
Divisional VP of Investor Relations and Corporate Social Responsibility
Phone: 302.498.5914
E-mail: mbooth@incyte.com

Lauren Ayala
Senior Director, Investor Relations
Phone: 302.498.6141
E-mail: layala@incyte.com

Computershare
P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536